Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators.

@article{Califf1997SelectionOT,
  title={Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators.},
  author={Robert M. Califf and Lynn H. Woodlief and Frank E. Harrell and Kerry L. Lee and Harvey Douglas White and Alan D. Guerci and Gabriel I. Barbash and Robert John Simes and William D. Weaver and Maarten L. Simoons and Eric J. Topol},
  journal={American heart journal},
  year={1997},
  volume={133 6},
  pages={630-9}
}
We developed a logistic regression model with data from the GUSTO-I trial to predict mortality rate differences in individual patients who received accelerated tissue plasminogen activator (TPA) versus streptokinase treatment for acute myocardial infarction. A nomogram was developed from a reduced version of this model that approximated the underlying risk of patients treated with streptokinase, and thus the benefit of TPA. The 30-day mortality rate with accelerated TPA was 0.063 versus 0.073… CONTINUE READING